Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 2Uveal Melanoma 1Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3trametinib 2pertuzumab 2dabrafenib 2Trastuzumab 2Tacrolimus 2Specimen Handling 2Polymerase Chain Reaction 2Nivolumab 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1tinostamustine 1temsirolimus 1sonidegib 1selinexor 1sapanisertib 1romidepsin 1relatlimab 1palbociclib 1osimertinib 1omipalisib 1merphos 1larotrectinib 1ipatasertib 1fludarabine phosphate 1erdafitinib 1entrectinib 1defactinib 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × GSK2141795 × Dermatologic × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡